Lung Transplant: Eligibility, Process, and Outcomes

Lung transplantation represents one of the most complex interventions in pulmonary medicine, offering a potential survival extension for patients with end-stage lung disease when all other treatments have been exhausted. This page covers the eligibility criteria used to evaluate candidates, the procedural stages from listing to recovery, the major disease categories that lead to transplant referral, and the clinical boundaries that determine when transplant is — and is not — appropriate. Understanding this landscape matters because transplant access is governed by both medical criteria and federal organ allocation policy.

Definition and Scope

A lung transplant is a surgical procedure in which one or both diseased lungs are replaced with donor lungs from a deceased individual. The United Network for Organ Sharing (UNOS), operating under contract with the federal Health Resources and Services Administration (HRSA), governs organ allocation in the United States through the Organ Procurement and Transplantation Network (OPTN). Allocation priority is determined by the Lung Allocation Score (LAS), a numerical index introduced by UNOS in 2005 that weights both transplant benefit and waitlist urgency to reduce deaths among candidates awaiting organs.

Transplants are classified by the number of lungs replaced:

1. Single lung transplant (SLT) — one lung is replaced; the native lung remains. Typically used for pulmonary fibrosis and some cases of COPD.
2. Bilateral sequential lung transplant (BSLT) — both lungs are replaced in sequence during a single operation. Required for suppurative diseases such as cystic fibrosis and bronchiectasis, where a retained native lung would contaminate the graft.
3. Heart-lung transplant — performed when irreversible cardiac dysfunction accompanies end-stage lung disease; accounts for fewer than 3% of thoracic transplants annually (ISHLT Registry).

The International Society for Heart and Lung Transplantation (ISHLT) publishes the primary registry data tracking outcomes across transplant centers worldwide.

How It Works

The transplant process moves through five discrete phases:

1. Referral and evaluation — A pulmonologist refers the patient to an accredited transplant center. The center performs a multi-disciplinary evaluation covering pulmonary function, cardiac status, nutritional state, renal function, psychosocial assessment, and absence of systemic contraindications.

2. Listing — If approved, the patient is registered with OPTN. The LAS, which ranges from 0 to 100, is calculated from forced vital capacity (FVC), six-minute walk distance, diagnosis category, and other variables. Higher LAS scores indicate greater urgency and translate to higher allocation priority.

3. Organ offer and acceptance — When a compatible donor organ becomes available, the transplant center has a defined window — typically 4 to 6 hours for cold ischemic tolerance — to accept and retrieve the lung. Donor-recipient matching considers blood type, size compatibility, and geographic proximity.

4. Surgery — Most bilateral transplants are performed via a clamshell (bilateral thoracosternotomy) incision. Cardiopulmonary bypass or extracorporeal membrane oxygenation (ECMO) may be used. Operative time ranges from 4 to 12 hours depending on complexity.

5. Post-transplant management — Patients receive lifelong immunosuppression, typically a three-drug regimen of a calcineurin inhibitor (tacrolimus or cyclosporine), an antiproliferative agent (mycophenolate mofetil), and a corticosteroid. Rejection surveillance is performed via bronchoscopy with transbronchial biopsy. Pulmonary rehabilitation is a standard post-transplant intervention to restore functional capacity.

According to ISHLT registry data, median survival after lung transplant is approximately 6.7 years for bilateral recipients and 4.8 years for single lung recipients, with 1-year survival exceeding 85% at experienced centers (ISHLT 2022 Registry Report).

Common Scenarios

Four diagnosis categories account for the majority of lung transplant listings in the United States, as reported in OPTN data:

• Chronic obstructive pulmonary disease / emphysema — historically the largest category; single lung transplant is often performed, though bilateral is increasingly preferred for younger patients due to improved long-term outcomes.
• Idiopathic pulmonary fibrosis (IPF) — characterized by rapid, unpredictable decline; high LAS scores make IPF patients among the most urgent candidates. The relationship between pulmonary fibrosis disease progression and waitlist mortality makes timely referral critical.
• Cystic fibrosis and bronchiectasis — bilateral transplant is mandatory. Patients with cystic fibrosis infected with Burkholderia cenocepacia face significantly higher post-transplant mortality and are considered a relative contraindication at most centers.
• Pulmonary arterial hypertension — bilateral transplant or heart-lung transplant depending on right ventricular recovery potential. The pulmonary hypertension disease trajectory typically requires transplant consideration when mean pulmonary artery pressure exceeds 55 mmHg with refractory symptoms.

For patients exploring the broader treatment and surgery for lung disease landscape, transplant occupies the most complex and resource-intensive position on the intervention spectrum.

Decision Boundaries

The ISHLT published updated consensus guidelines in 2021 establishing referral and listing thresholds by disease category. Several factors define the outer boundaries of candidacy:

Favorable listing criteria include:
- Predicted two-year survival without transplant below 50%
- BODE index greater than 7 for COPD (accounting for body mass index, airway obstruction, dyspnea, and exercise capacity)
- Diffusing capacity for carbon monoxide (DLCO) below 40% predicted in IPF
- Six-minute walk distance below 250 meters

Absolute contraindications recognized by ISHLT include:
- Active malignancy within 2 years (most solid tumors); 5 years for certain cancers
- Untreatable extrapulmonary organ dysfunction
- Uncorrectable bleeding diathesis
- Active mycobacterial infection without effective treatment regimen
- Documented non-adherence or inability to comply with post-transplant immunosuppression

Age is not a strict cutoff, but most centers apply conservative thresholds, typically limiting single lung transplant to candidates under 65 and bilateral transplant to candidates under 60, with case-by-case exceptions.

The regulatory and oversight framework governing transplant center accreditation and outcome reporting falls under CMS Conditions of Participation for Transplant Centers (42 CFR Part 482, Subpart E), which mandate outcome tracking and public reporting. The broader regulatory context for pulmonary medicine intersects with transplant policy through HRSA oversight of OPTN and mandatory reporting requirements for center-specific survival data.

The pulmonaryauthority.com index provides orientation across the full spectrum of pulmonary conditions and interventions covered within this reference network.

References

• UNOS / OPTN — Organ Procurement and Transplantation Network
• HRSA — Health Resources and Services Administration, Organ Transplantation
• ISHLT — International Society for Heart and Lung Transplantation Registry
• ISHLT Consensus Document: A Consensus Document for the Selection of Lung Transplant Candidates (2021 Update)
• CMS Conditions of Participation for Transplant Centers — 42 CFR Part 482, Subpart E
• OPTN Lung Allocation Policy Documentation

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)